Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) CEO Purchases $102,776.38 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela purchased 39,682 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the acquisition, the chief executive officer owned 1,065,215 shares in the company, valued at approximately $2,758,906.85. This trade represents a 3.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TriSalus Life Sciences Stock Up 2.9%

TLSI stock opened at $3.24 on Thursday. The firm has a market cap of $198.64 million, a PE ratio of -2.30 and a beta of 0.56. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. The firm’s 50 day moving average price is $4.09 and its 200-day moving average price is $5.09. TriSalus Life Sciences, Inc. has a one year low of $2.20 and a one year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $13.20 million. On average, equities research analysts anticipate that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on TLSI. Lake Street Capital reduced their price target on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Weiss Ratings lowered shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLSI. JPMorgan Chase & Co. raised its position in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences in the second quarter valued at approximately $47,000. Invesco Ltd. purchased a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $72,000. Abel Hall LLC purchased a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $73,000. Finally, HighMark Wealth Management LLC purchased a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $75,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.